Ingen appoints director of r&d

Aims to increase sales of in vitro diagnostic (IVD) kits

Ingen Biosciences, a French developer of advanced in vitro diagnostic kits for clinical use, has appointed Karine Mignon-Godefroy as director of research & development.

Mignon-Godefroy joins the firm to generate sales of its first proprietary in vitro diagnostic (IVD) kit. These IVD kits are based on the firm’s specialist knowledge in proteomics and expertise in synthesising new recombinant antigens. Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens as potential markers for the detection of infectious diseases found in prosthetic replacements, and to develop innovative IVD kits for clinical use.

‘Dr Mignon-Godefroy’s 15 years’ experience in biotechnology, depth of knowledge and skills will be a major contribution to our on-going r&d efforts,’ said Jean-Pierre Hermet, chief executive of Ingen Biosciences. ‘Her arrival will also strengthen the team, which has made significant inroads into developing products based on innovative technologies.'

Mignon-Godefroy joins Ingen Biosciences from the blood virus division of Bio-Rad, a manufacturer and distributor of products for a range of technologies including proteomics, where she was director of international projects.

You may also like

Regulatory

Standard proposed to clarify endotoxin testing for single-use systems

The guide will address variability when assessing bacterial endotoxins on large-scale pharmaceutical equipment
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Regulatory

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma announces that the US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440
Manufacturing

Molecular Devices unveils next-generation SpectraMax Multi-Mode Microplate Readers

Honouring a legacy of product line reliability and strength, the SpectraMax Multi-Mode Microplate Readers have been transformed with next-generation innovation to improve research capabilities and provide unparalleled flexibility for a wide range of assays and applications
Manufacturing

Merck launches AAW Workstation to advance lab automation

New platform powered by Opentrons expands lab automation to accelerate scientific discovery
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Siemens recognition for Bürkert enables improved development

The new partnership will extend integration capabilities for OEMs and end users with a focus on valve islands for process industries
Subscribe now